Navigation Links
New Options for Treatment of RA and Lupus are Focus of Rheumatology Thought Leader Panel
Date:11/6/2009

SCOTTSDALE, Ariz., Nov. 6 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis (RA) and lupus.

"Of all the diseases rheumatologists treat, lupus still has the highest unmet need," according to MedPredict president Jeffrey Berk. "While many more people have RA than have lupus, lupus kills, and RA doesn't. There are a plethora of good therapies for RA, but few for lupus. This expert panel weighs in on the leading B-cell inhibitors that are in development for lupus, and provides insight into how different lupus trial designs have thus far driven clinical outcomes."

To develop this analysis, entitled "Thought Leader Insight & Analysis: Rheumatology," MedPredict conducted primary interviews with U.S.-based rheumatology thought leaders around the time of the recent American College of Rheumatology 2009 conference.

Some of the issues analyzed in this report:

  • Reactions to pivotal Phase III data supporting GlaxoSmithKline's Benlysta (belimumab) in systemic lupus erythemetosis (SLE).
  • Impact of the FDA's complete response letter rejecting Genentech's application for Rituxan (rituximab) in RA patients who have previously failed DMARD therapy - do thought leaders think PML safety concerns apply to all B-cell inhibitors?
  • Insight into rheumatologists' decision-making process for selecting treatment for RA. How will anti-TNF newcomers fit into the rheumatologist's armamentarium?
  • Role of other mechanisms, including CTLA4, IL-6, IL-17, JAK, Syk, TNF/PDE4, BTK, MEK, and S1P.

Companies/Partnerships mentioned in this report include: Abbott, Alder, Amgen/Pfizer, Arana, Array, AstraZeneca/MedImmune, Bristol-Myers Squibb, Celgene, Centocor/Schering-Plough, Cytopia, Genentech/Roche, Genentech/Roche/Chugai, GlaxoSmithKline/Genmab, GSK/Human Genome Sciences, Incyte, Lexicon, Lilly, Merck, Merck Serono/ZymoGenetics, Novartis, Pharmacyclics, Rigel, UCB, UCB/Immunomedics, Pfizer/Trubion.

This report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict


'/>"/>
SOURCE MedPredict
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Radiation Therapy Options in Mesothelioma by Veronica Garza of MD Anderson Sponsored by MesoCare.org
2. Clinical Care Options Launches CCO HIV inPractice, a Unique, Free, Comprehensive Online Resource for Healthcare Providers at the Point of Care
3. October 2009 Mayo Clinic Womens HealthSource Highlights Ductal Carcinoma In Situ, New Hearing Aid Options and Self-Acceptance
4. Survey Reveals Parents Are Eager to Learn about Alternative Medicine Options but Information is Lacking
5. On World Menopause Day, October 18, The International Menopause Society and World Health Organization Urge Women to Learn About Their Options for Dealing With Menopause
6. SIMNSA is added to the Satori Global Network™ in Mexico to Offer U.S. Employers Cross Border Health Benefit Options
7. Proposed Medicare Changes Will Increase Costs to Government, Decrease Options for Patients
8. A Staggering 7 Out of 10 Women Facing Breast Cancer Are Never Told of Their Options
9. EdOptions(TM) Offers Schools Affordable Solution to Ensure Continuity of Learning
10. Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options
11. New Directions in Angioedema: A Focus on Supportive Care and Treatment Options
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
Breaking Medicine Technology: